Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P46777
UPID:
RL5_HUMAN
Alternative names:
60S ribosomal protein L5
Alternative UPACC:
P46777; Q32LZ3; Q53HH6; Q9H3F4
Background:
The Large ribosomal subunit protein uL18, also known as 60S ribosomal protein L5, is a pivotal component of the ribosome, essential for protein synthesis. It plays a critical role in the formation of the large ribosomal subunit (LSU) and the maturation of rRNAs. This protein is involved in coupling ribosome biogenesis to p53/TP53 activation, highlighting its significance in cellular processes.
Therapeutic significance:
Given its crucial role in ribosome biogenesis and its involvement in Diamond-Blackfan anemia 6, targeting Large ribosomal subunit protein uL18 presents a promising avenue for therapeutic intervention. Understanding the role of Large ribosomal subunit protein uL18 could open doors to potential therapeutic strategies.